Stay updated on Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest updates to the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.2%
- Check19 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, while removing the previous wording about those conducting the study.SummaryDifference7%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedNew features have been added to the website, while several options related to data downloads and study details have been removed.SummaryDifference9%
- Check41 days agoChange DetectedSeveral key health-related resources, including MedlinePlus and FDA links, have been removed, which may impact access to important genetic and medical information.SummaryDifference1%
- Check48 days agoChange DetectedThe website has been updated to version 2.12.2, adding several new resources related to genetics, breast cancer, and drug information, while removing the previous version 2.12.1.SummaryDifference12%
- Check55 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.2%
Stay in the know with updates to Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.